Different immunomodulatory strategies are currently under investigation in preclinical AD models for Reelin potential therapeutic impact in reducing amyloidosis and regulating neuroinflammation [59,60,61,62,72,73,74,75,76]. The gene discussed is RELN; the disease is Alzheimer disease.